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Immunogiobulins bind through  their  Fc  regions to  specific  receptors  on  macro- 
phages. On mouse macrophages, there are at least two such Fc receptors: one which 
binds the mouse IgG2a subclass and a second which binds mouse IgG2b and probably 
IgGl  as  well  (1-4).  Recently,  we  have  used  pure  preparations  of  homogeneous 
(hybridoma) anti-sheep erythrocytes (SRBC) antibodies to confirm the presence and 
subclass specificity of the macrophage receptors for IgG2a and IgG2b (3).  That these 
two receptors are discrete has also been shown by isolating variant macrophage cell 
lines which either lack or have alterations in one of these two Fc receptors (2, 3). 
In the experiments to be described in this paper, we have used immunoglobulins 
with heavy-chain deletions or recombinations, produced by variants of the MPC  11, 
IgG2b-producing, mouse myeloma cell line to determine the portion of the Fc region 
of IgG2b which binds to the mouse Fc receptors. With these variants we have shown 
that  the  mouse  macrophage  Fc  receptor  for  IgG2b recognizes a  site(s)  in  the  CH2 
domain of the IgG2b molecule. 
Materials and Methods 
Cells.  The  use  of J774.2,  FC-I,  and  peritoneal  macrophages  to  study  macrophage  Fc 
receptors  has  been  described  previously (3). J774  is  a  mouse  reticulum cell  sarcoma  with 
macrophage-like  properties  which  was  adapted  to  culture  by  repeated  passage  between 
BALB/c mice and tissue culture. J774.2 is a subclone of the tissue culture line which stably 
secretes ~ 10/zg of lysozyme/10  ~ cells per 24 h. FC-1 is a macrophage-like cell line which arose 
during the fusion of a thioguanine-resistant  subclone (45.6 TG1.7) (3) of the MPC  11, IgG2b, 
K-producing mouse myeloma cell line to spleen cells from a  BALB/c mouse immunized with 
SRBC. 
Peritoneal cells were obtained from untreated BALB/c mice as previously described (3). 
Tissue culture cells  were  maintained in  Petri  dishes  (Falcon Labware,  Div.  of Becton, 
Dickinson, & Co.,  Oxnard,  Calif.)  in Dulbecco's modified Eagle's medium  (H-21)  (Grand 
Island  Biological  Co.,  Grand  Island,  N.  Y.)  supplemented  with  penicillin, streptomycin, 
glutamine, nonessential amino acids,  20%  heat-inactivated horse serum  (Flow Laboratories 
Inc., Rockville, Md.), and 10% NCTCI09 (Microbiological Associates, Walkerville, Md.). 
Myeloma Proteins.  Approximately l0  T  cells were injected into the peritoneal cavity of Pristane 
(2.6,10,14-Tetramethylpentadecane, Aldrich  Chemical  Co.,  Inc.  Milwaukee,  Wis.)  treated 
BALB/c mice (5). The ascites  fluid which formed was removed, separated from the cells, and 
precipitated with 50% saturated ammonium sulfate. Purified immunoglobulins  from MPC  11 
and MOPC  173  were obtained by two steps  of ion-exchange chromatography  (3). Variant 
proteins were also purified by ion-exchange chromatography using an alternate buffer system 
(6). Purified proteins were examined for contaminating  proteins of another subclass by agarose 
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Volume 150  September 1979  721-726 gel electrophoresis (7) and by Ouchterlony analysis with commercial subclass-specific  antisera 
(Meloy Laboratories Inc., Springfield, Va.)  or with our own antisera which have been made 
subclass specific on immunoadsorbant columns. The preparations used in the studies reported 
below contained no detectable contamination with other subclasses. 
The Fc fragments of MPC  11,  ICR  11.19.3, and  ICR 9.9.2.1  were isolated  as previously 
described (6). 
Preparation of Ig-coated SRBC.  The methods described by Bianco et al.  were used  (8). The 
mouse antisera were from multiply recloned anti-SRBC hybridomas which no longer make the 
myeloma heavy chain. 
Fc Rosettes.  Glass coverslips were sterilized and placed in 25-cm  2 Petri dishes. Approximately 
5  ×  l0  s cells  were added  in  5  ml  of medium  and  incubated  overnight.  To assay rosettes, 
coverslips were removed, covered with Ig-coated SRBC, and  incubated at  37°C for 30 min. 
They were then  rinsed  in  Hanks' balanced  salt  solution and  100 cells  were assayed for the 
presence of rosettes.  Attachment of three or more SRBC signified a rosette. 
Purified proteins were used to inhibit rosette formation at a concentration of 100/~g/ml in 
phosphate-buffered saline, aggregated either with bisdiazotized benzidine (BDB)  (9) or with 10 
/~1 of a  rabbit  anti-mouse It-chain antiserum.  The optimal  amount  of anti-~¢ antiserum  was 
determined by titering it with a fixed amount of myeloma protein and selecting the antigen- 
antibody  mixture  which  inhibited  rosetting  of antibody-coated  SRBC.  Macrophages  were 
pretreated for 15 min with purified myeloma protein after which Ig-coated SRBC were added. 
After 30 rain, cells were examined for rosette formation. 
Results 
Controls for the Binding of Antibody-coated SRBC by Macrophages.  SRBC  coated  with 
either monoclonal IgG2b or IgG2a anti-SRBC antibody will rosette with Fc receptors 
on  two  macrophage  cell  lines, J774.2  and  FC1,  and  on  primary  peritoneal  macro- 
phages  (3).  As shown  previously,  rosetting  of IgGza-coated SRBC  was  inhibited  by 
aggregated  MOPC  173  (IgGza)  protein  and  not  by  aggregated  MPC  11  (IgG2b) 
protein, whereas rosetting of IgG2b-coated SRBC was inhibited  by aggregated  MPC 
11  protein  but  not  by MOPC  173 protein  (Table  I  A). As a  further  control  for the 
specificity of the  Fc receptors,  ICR 9.9.2.1  was used.  This  variant  immunoglobulin 
contains  the  idiotype of the  parental  MPC  11  protein  (7),  has  a  normal  molecular 
weight, and the sequence of its Fc region is that of IgG2a (6).  It inhibited  the binding 
of IgG2a-coated SRBC and not of IgG2b-coated SRBC (Table I A). This showed that 
a  variant  immunoglobulin would behave as predicted  from the primary sequence of 
its Fc region. 
Binding of M 311.  M  311, a variant having a short heavy chain with a deleted CH3 
domain  (10,  11,  and  A.  Kenter  and  B.  K.  Birshtein,  unpublished  data),  inhibited 
binding of IgG2b-coated SRBC but not of IgG2~-coated SRBC (Table I A). This result 
suggested  that  an  intact  CH3  domain  is  not  required  for  IgG2b to  bind  to  the  Fc 
receptor. Because this was our first indication that the Cn2 domain might be involved 
in  binding,  we wanted  to rule out  the  possibility  that  BDB treatment  had exposed 
previously hidden and perhaps nonphysiologic Fc binding sites on the M  311 protein. 
Therefore,  M  311  was  independently  aggregated  with  rabbit  anti-mouse  K-chain 
antibody. The antibody-aggregated protein also inhibited rosette formation and again 
showed IgG2b subclass specificity (Table I B). 
Binding ofICR 11.19.3.  The variant protein produced by ICR 11.19.3 contains the 
MPC  11  idiotype (7), ]gG2b sequences in the N-terminal  portion of the heavy chain, 
and  IgG2~ sequences  throughout  its Cn3 domain  (12).  The cross-over point between 
IgG2b and IgGza sequences seems to lie in the C-terminal segment of the CH2 domain, 
(B.  K.  Birshtein,  R.  Campbell,  and  M.  L.  Greenberg,  manuscript  in  preparation). 
When aggregated, this protein inhibited rosette formation with both IgG2~- and ]g~2b- 
coated  SRBC  (Table  I  A).  The  inhibition  was,  however,  less complete  for each  Fc 
receptor than with the appropriate normal immunoglobulin. 
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Cell line  Inhibitor 
IgGzb-SRBC  IgGz,,-SRBC 






%  %  %  % 
--  98  --  100  -- 
MPC  11  7  94  83  17 
MOPC 173  88  11  19  81 
ICR 9.9.2.1  90  10  15  85 
M  311  5  95  93  7 
ICR 11.19.3  34  66  35  65 
--  97  --  97  -- 
MPC 11  11  89  95  3 
MOPC 173  88  10  18  82 
ICR 9.9.2.1  88  10  20  80 
M  311  7  93  90  8 
ICR 11.19.3  29  70  29  70 
--  88  --  87  -- 
MPC 11  9  90  83  5 
MOPC 173  86  4  21  76 
ICR 9.9.2.1  83  7  14  84 
M  311  6  94  84  4 
ICR 11.19.3  26  71  26  71 
--  97  --  100  -- 
MPC 11  13  87  90  10 
MOPC 173  89  9  19  81 
M  311  (BDB aggregated)  5  95  93  7 
M  311  (rabbit anti-K)  8  92  89  11 
--  100  --  99  -- 
ICR 9.9.2.1  Fc  95  5  17  83 
ICR 11.19.3 Fc  33  67  38  72 
MPC 11 Fe  11  89  93  7 
Binding of Fc Fragments.  Aggregated  Fc fragments of MPC  11,  ICR 9.9.2.1,  and 
ICR  11.19.3  inhibited  rosette  formation  in  the  same way  as  the  intact  molecules 
(Table I  C). This result implies that neither the Fab fragment nor the CH1  domain 
are required to stabilize the Fc fragment for binding to an Fc receptor. 
Discussion 
The constant region of the IgG molecule contains three domains of ~-110 residues 
each. These domains are homologous in amino acid sequence to each other and to the 
corresponding  domains  of other  immunoglobulin  classes.  The  sequences  of mouse 
IgG2a and IgG2b constant regions are of special interest to the studies reported here. 
The complete sequence of the IgG~ constant  region was determined by Fougereau 
and colleagues (13).  Recently we have reported partial amino acid sequences in the 
IgG2b Fc  region  (6).  The CH2  domains  of mouse  IgGz~ and  IgG2b are very similar 
because of the 66 residues determined, only 8 are different. The CH3 domain shows 
more differences;  in  the C-terminal  34 residues  alone,  IgG2b and IgG2a differ in  20 
positions. 
Each domain  is folded into a  relatively independent  tertiary structure which  has 
been postulated by Edelman and Gall to be responsible for different functions of the 
immunoglobulin molecule (14). The aim of these studies was to use variant myeloma 
proteins to try to determine which parts of the mouse heavy chain react with the Fc 
receptors on  mouse macrophages. Whereas  alterations  or deletions  in  these variant 
723 molecules may cause a  change  in  folding, it was  hoped  that  the use of the  intact 
proteins would minimize the possibility both of exposing new sites for macrophage 
binding and of obscuring sites that require stabilization from adjacent portions of the 
molecule. 
We used three homogeneous myeloma proteins with altered heavy chains to inhibit 
the binding of monoclonal antibody-antigen complexes to Fc receptors on two mouse 
macrophage  cell  lines  and  on  primary  peritoneal  macrophages.  The ICR  9.9.2.1. 
protein, which appears identical in its Fc region to the IgG2a protein, MOPC  173(6) 
and bound only to the IgG2a Fc receptor, served as an internal control to demonstrate 
that a  variant immunoglobulin would display the subclass specificity expected from 
its linear sequence. The two other variant proteins, M  311  and ICR  11.19.3,  bound 
specifically  to  the  IgG2b  Fc  receptor.  Knowledge of their  sequences  allows  us  to 
conclude that  the CH2 domain is involved in the binding of mouse IgG2b to mouse 
macrophage Fc receptors because in both variants the CH3 domain of IgG2b is missing: 
M  311  totally lacks  any CH3  domain  (10,  11, and  A.  Kenter and  B.  K.  Birshtein, 
unpublished observations) and ICR  11.19.3  has a CH3 domain that is entirely IgG2a- 
like (B. K. Birshtein, R. Campbell, and M. L. Greenberg, manuscript in preparation). 
The recombinant molecule, ICR  11.19.3,  is less effective than either normal IgG2b 
or M  311  in binding to the IgG2b Fc receptor. This finding could be explained if the 
cross-over has  occurred within  the  sequence(s)  that  makes  contact  with  the  IgG2b 
receptor or if the contact residues are all present but have changed in their tertiary 
structure, availability, or stability because of new neighboring sequences. The recom- 
binant molecule also specifically inhibited the binding of IgG~ to the IgG2~ receptor, 
but again this inhibition was partial and the same possible explanations exist. The 
data do not  prove domain specificity for the binding of IgG2~ but  do suggest  that 
binding can occur through some sequences located between the terminal portion of 
the Ca2 domain and the end of the CH3 domain. 
Our  results  therefore implicate  the  CH2  domain  in  the  binding  of at  least  one 
subclass of mouse immunoglobulin to mouse macrophage receptors. Some previous 
studies have shown a similar result. For example, Huber et al. have found Fc receptor 
binding  activity  in  the  F(ab')2  fragments  of human  IgG  (15).  In  the  guinea  pig, 
Alexander et al.  (16)  studied the binding of IgG2 to peritoneal macrophages. They 
found that  an intact Cri2 domain was required for cytophilic binding and that  the 
interchain disulfide bonds stabilized  the  binding site.  Ovary et  al.  found that  the 
fragment  of rabbit  IgG lacking the  CH3  domain  (Facb)  binds  to  guinea  pig  lung 
macrophages whereas the CH3 fragment alone does not (17). 
However, many other studies which have used heterologous systems, heterogeneous 
antibodies and a  variety of assays, have implicated the CH3  domain.  For example, 
Yasmeen et al. (18) using a heterologous system, found that human IgGx bound to the 
Fc receptor of guinea pig macrophages through the Cn3 domain. They showed that 
CH3-coated SRBC could bind  to macrophages;  in  addition, they could inhibit  the 
binding of whole protein to macrophages with unaggregated CH3 fragments. Okafor 
et al. (19) used a homologous system in which they studied the binding of unfraction- 
ated human  IgG to human  monocytes. They tested the CH3  fragment of each IgG 
subclass  for its  ability  to  inhibit  the  binding  of whole,  unfractionated  IgG-coated 
RBC and found that the CH3 fragments of IgG1 and IgG8 were effective although not 
so effective as unfractionated IgG. 
Dissanayake  and  Hay  have  studied  the  question  of Fc  binding  using  mouse 
myeloma proteins and mouse macrophages. They found direct binding of unaggre- 
724 gated IgG1, IgG2~ and IgG2b, and of the unaggregated CH3 domains of Iggl and [gG2b 
to macrophages (20).  However, other results (1, 21) in the mouse systems sugest that 
at least some of the IgG subclasses will not bind to Fc receptors unless aggregated. 
It  is  possible  that  Fc  receptors on  various cell  types differ in  their  specificity in 
binding.  Ramasamy et al. (22)  were unable to inhibit rosette formation of heteroge- 
neous  Ig-coated  RBC  to  mouse  lymphocytes with  a  mouse  IgG1  immunoglobulin 
missing the  CH3  domain.  They therefore suggested  a  site in  the CH3  domain  was 
responsible for the binding of IgGx to lymphocytes. On mouse macrophages, a single 
Fc receptor seems to recognize both  IgGa and  IgG2b, and the studies  reported here 
show  that  a  site in  the Cn2  domain  is responsible for the binding of IgG2b to this 
receptor. Consequently,  either IgGx and IgG2b bind to a  single Fc receptor through 
different domains or Fc receptors on lymphocytes differ from those on macrophages. 
Fc receptors on other cell types and in different species might also differ. For example, 
experiments by McNabb et al. showed that human IgG binds to macrophages through 
the CH3 domain although it binds to Fc receptors on human placental tissue through 
sites in both  the CH2 and CH3 domains  (23).  In rabbits,  however, Tsay and  Schla- 
mowitz have shown that rabbit IgG binds to rabbit yolk sac membrane through the 
CH2 domain (24). 
These differing results suggest that different subclasses of IgG may have different 
domains for binding to Fc receptors. Different cell types may have Fc receptors with 
different specificities. Different species may have the sequences responsible for certain 
functions localized in different domains. 
The  experiments  reported  in  this  paper use  a  homologous  murine  system  with 
homogeneous reagents to show the binding of the CH2 domain of IgGzb to macrophage 
Fc  receptors.  These  results  also  demonstrate  the  potential  usefulness  of  variant 
immunoglobulins in probing the determinants responsible for the effector functions 
of immunoglobulins. The combined use of homogeneous antibodies and such variant 
proteins should make it possible to compare the specificity of Fc receptors on a variety 
of cell types. 
Summary 
Three mouse immunoglobulins with altered heavy chains have been used to study 
the specificity of the mouse [gG2b Fc receptor on mouse macrophages. These immu- 
noglobulins  were  synthesized  by  variant  clones  derived  from  the  MPC  11,  IgG2b- 
producing mouse myeloma cell line. One variant, whose Fc seems identical to that of 
an  IgG2a myeloma protein  of known  sequence,  binds  specifically  to  the  IgG~  Fc 
receptor. A second variant, which makes a short heavy chain lacking the Cn3 domain, 
binds specifically to the IgG2b Fc receptor. The third variant makes a  hybrid IgG2b- 
IgG2a heavy chain whose Cn3  domain is entirely IgG2~-like and binds to both IgG2~ 
and IgG2b Fc receptors. These data suggest that the binding of mouse IgG2b immu- 
noglobulins  to  the  mouse  macrophage  Fc  receptor  involves  a  site  within  the  CH2 
domain  and  indicate  that  immunoglobulins with altered  heavy chains  are a  useful 
tool to probe Fc receptors. 
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